

Andrea Napolitano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5988752/publications.pdf>

Version: 2024-02-01

71
papers

2,666
citations

257450

24
h-index

189892

50
g-index

73
all docs

73
docs citations

73
times ranked

3853
citing authors

#	ARTICLE	IF	CITATIONS
1	Current management of benign retroperitoneal tumors. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1081-1090.	1.0	3
2	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
3	KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. <i>Chemotherapy</i> , 2022, 67, 81-90.	1.6	10
4	Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2477.	4.1	7
5	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
6	Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors. <i>Journal of Bone Oncology</i> , 2022, 34, 100422.	2.4	2
7	Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2435.	3.7	15
8	Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. <i>Cancers</i> , 2021, 13, 652.	3.7	19
9	Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLs). <i>Journal of Clinical Oncology</i> , 2021, 39, 11509-11509.	1.6	3
10	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021, 11, 682449.	2.8	16
11	Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. <i>Cells</i> , 2021, 10, 1533.	4.1	14
12	S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. <i>Chemotherapy</i> , 2021, 66, 1-8.	1.6	1
13	Recent Advances in Desmoid Tumor Therapy. <i>Cancers</i> , 2020, 12, 2135.	3.7	18
14	Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study. <i>Oncology</i> , 2020, 98, 893-896.	1.9	2
15	Expression of Concern: HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 1529-1529.	7.0	2
16	Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer. <i>European Thyroid Journal</i> , 2020, 9, 157-161.	2.4	4
17	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 95.	8.6	147
18	Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	4.5	11

#	ARTICLE	IF	CITATIONS
19	Current and Emerging Biomarkers Predicting Bone Metastasis Development. <i>Frontiers in Oncology</i> , 2020, 10, 789.	2.8	8
20	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 959-964.	3.1	18
21	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	3.1	12
22	Prognostic and predictive factors in pancreatic cancer. <i>Oncotarget</i> , 2020, 11, 924-941.	1.8	46
23	Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O):A real-world study on behalf of Meet-URO group (MeetUro-7b).. <i>Journal of Clinical Oncology</i> , 2020, 38, e17088-e17088.	1.6	0
24	Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11533-11533.	1.6	0
25	Role of glyoxalase-1 in trabectedin-resistant myxoid liposarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23566-e23566.	1.6	0
26	Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. <i>Chemotherapy</i> , 2019, 64, 105-109.	1.6	14
27	Unexpected benefit from an α -old α ™ metronomic chemotherapy regimen in advanced chordoma. <i>BMJ Case Reports</i> , 2019, 12, e228728.	0.5	2
28	New frontiers in the medical management of gastrointestinal stromal tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984194.	3.2	33
29	PDGFR \pm inhibition in soft-tissue sarcomas: Have we gotten it all wrong?. <i>EBioMedicine</i> , 2019, 40, 37-38.	6.1	2
30	Secondary KIT mutations: the GIST of drug resistance and sensitivity. <i>British Journal of Cancer</i> , 2019, 120, 577-578.	6.4	41
31	Splicing molecular biology and novel therapies in diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019, 39, 7-8.	6.1	0
32	Predicting the Risk of Recurrence in Retroperitoneal Sarcoma. <i>Updates in Surgery Series</i> , 2019, , 143-153.	0.1	0
33	Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22540-e22540.	1.6	0
34	Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11053-11053.	1.6	0
35	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018, 95, 1-7.	1.9	7
36	Progress in the Management of Malignant Pleural Mesothelioma in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 606-623.	1.1	67

#	ARTICLE	IF	CITATIONS
37	A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of <i>BAP1</i> and Other Germline Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 3485-3494.	1.6	104
38	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	3.2	27
39	FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11556-11556.	1.6	1
40	BAP1 regulates IP3R3-mediated Ca ²⁺ flux to mitochondria suppressing cell transformation. <i>Nature</i> , 2017, 546, 549-553.	27.8	308
41	Improving the Accuracy of Mesothelioma Diagnosis in China. <i>Journal of Thoracic Oncology</i> , 2017, 12, 714-723.	1.1	43
42	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	4.4	16
43	Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. <i>Oncogene</i> , 2017, 36, 6501-6507.	5.9	17
44	FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. <i>Journal of Translational Medicine</i> , 2017, 15, 58.	4.4	19
45	Germline BAP1 mutations induce a Warburg effect. <i>Cell Death and Differentiation</i> , 2017, 24, 1694-1704.	11.2	105
46	HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. <i>Oncotarget</i> , 2017, 8, 22649-22661.	1.8	43
47	Abstract 5763: Investigating the carcinogenic potential of various types of mineral fibers in the development of mesothelioma. , 2017, , .		0
48	Malignant Mesothelioma: Time to Translate?. <i>Trends in Cancer</i> , 2016, 2, 467-474.	7.4	14
49	Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2016, 19, 213-230.	6.5	24
50	High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13432-13437.	7.1	130
51	HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3087-3096.	7.0	98
52	Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. <i>Oncogene</i> , 2016, 35, 1996-2002.	5.9	142
53	Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. <i>Oncotarget</i> , 2016, 7, 59314-59321.	1.8	54
54	Abstract 3112: HMGB1 and its isoform are sensitive and specific biomarkers to detect asbestos exposure and to identify mesothelioma patients. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
55	Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genetics, 2015, 11, e1005633.	3.5	76
56	Concerns About Presence of a Wild-TypeBAP1Allele in Absence of Nuclear Protein Expression. JAMA Dermatology, 2015, 151, 1265.	4.1	0
57	Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death and Disease, 2015, 6, e1786-e1786.	6.3	61
58	Preclinical development of Hlvax: Human survivin highly immunogenic vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 1585-1595.	3.3	14
59	Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Review of Respiratory Medicine, 2015, 9, 633-654.	2.5	46
60	Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis, 2015, 36, 76-81.	2.8	202
61	Abstract 4796: A founder mutation in the BAP1 gene among four caucasian families with high incidences of malignant peritoneal mesothelioma and uveal melanoma: a molecular and genealogical study in a 10-generation BAP1 cancer syndrome kindred. , 2015, , .		0
62	Evaluation of clonal origin of malignant mesothelioma. Journal of Translational Medicine, 2014, 12, 301.	4.4	80
63	Abstract 446: BAP1 mutation in mesothelioma and "BAP1 Cancer Syndrome", 2014, , .		0
64	Continuous Exposure to Chrysotile Asbestos Can Cause Transformation of Human Mesothelial Cells via HMGB1 and TNF- α Signaling. American Journal of Pathology, 2013, 183, 1654-1666.	3.8	88
65	Abstract C187: Salicylates suppress tumor growth via inhibition of HMGB1.. , 2013, , .		0
66	Evidence-based guidelines: Improving AGREement on consistence evaluation. Journal of Bone Oncology, 2012, 1, 30-34.	2.4	0
67	BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. Journal of Translational Medicine, 2012, 10, 179.	4.4	268
68	Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. Journal of Hematology and Oncology, 2012, 5, 56.	17.0	38
69	Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opinion on Investigational Drugs, 2011, 20, 1685-1705.	4.1	4
70	Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Annals of Oncology, 2011, 22, 1141-1146.	1.2	54
71	Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics, 2010, 11, 865-878.	1.3	21